|CCL 06.05.07 Discovery & Selection of Successful Drug Candidates, Boston, MA|
From: chemistry-request at ccl.net
To: chemistry-request at ccl.net
Date: Wed Feb 1 09:42:42 2006
Subject: 06.05.07 Discovery & Selection of Successful Drug Candidates, Boston, MA
Discovery & Selection of Successful Drug Candidates MAY 7 - 10, 2006 | ROYAL SONESTA HOTEL BOSTON CAMBRIDGE, MA http://www.chemistry.org/portal/a/c/s/1/acsdisplay.html?DOC=acsprospectives%5c06drugcandidates%5cindex.html For the second annual conference on the Discovery & Selection of Successful Drug Candidates, chairs Dr. Andrew Combs, Senior Director of Discovery Chemistry at Incyte, and Dr. Gregory Roth, Associate Director of Medicinal Chemistry at Abbott Bioresearch Center, have again intentionally organized the agenda to shed light on the process of drug discovery itself instead of by a specific disease area. Keynoting the conference will be Roy Vagelos, former CEO of Merck, who will give his view on the state of the drug discovery industry and its f uture. Then the program explores four key aspects of drug discovery -- lead discovery, structure-based drug design, selectivity issues, and ADME/tox issues -- with a half days session devoted to each. On the last day of the conference, the VPs of medicinal chemistry for Merck, Novartis, and GSK will present case studies on drugs that have advanced through proof of concept or been successfully marketed. They will share their perspectives on how they were discovered, lessons learned, and how they have instituted those lessons into their current drug discovery processes. Last year this conference sold out early, so please register soon to guarantee a seat. Confirmed Speakers: * On Lead Discovery: - Phil Hajduk of Abbott on fragment-based approaches to NMR -- Protein NMR in Drug Discovery & Design - Miles Congreve of Astex Therapeutics on fragment based approaches to X-ray -- "From Fragment to Clinic: Fragment Based Drug Discovery" - Dan Veber of Tranzyme Pharma "Discovery of a Cathepsin K Clinical Candidate" - Jon Collins of GSK "Structure-Guided Design of a Pathway Selective LXR Modulator" * On Structure-based Drug Design: - Robert Perni of Vertex "Designing an Inhibitor of a Recalcitrant Enzyme: The Tale of VX-950 and the HCV NS3-4A Protease" - F. George Njoroge of Schering-Plough "Challenges & Successes in Discovering Protease Inhibitors for the Treatment of Hepatitis C Virus" - Dan Goldberg of Boehringer Ingelheim "Discovery & Optimization of p38 Inhibitors via Computer Assisted Drug Design" - Vinod Patel of Amgen "Discovery & Properties of AMG 706, A KDR Inhibitor in Phase II Clinical Trials " * On Selectivity: - Ann Weber of Merck "Discovery of Sitagliptin, A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes" - Laura Blumberg of Pfizer "Discovery & Development of Human Specific CCR1 Receptor Antagonists" - Don Pinto of BMS "The Discovery of Apixaban, A Potent & Orally Bioavailable Coagulation Factor Xa Inhibitor" * On ADME/Tox: - Bruce Car of BMS "Discovery Preclinical Strategies for Reducing Toxicology-related Attrition" - Mark Bunnage of Pfizer "Small Polar Drugs" - Phaik-Eng Sum of Wyeth "Tygacil: A Newly Approved Expanded Broad-Spectrum Antibiotic" - Dale Kempf of Abbott "HIV Protease Inhibitors" * VPs of Medicinal Chemistry presentations: - Robert Zamboni of Merck "Discovery of SINGULAIRTM" - Martin Missbach of Novartis "Selective & Orally Active Inhibitors of Cathepsin K: A Novel Treatment for Osteoporosis?" - John Elliott of GSK "Eltrombopag, A Small Molecule Thrombopoietin Agonist" Short Course (Optional) * Warren Wade, Director of Medicinal Chemistry, and Ajay Madan, Director of Metabolism, both of Neurocrine, will review the typical biological results that are used to select for drug candidates, with an emphasis on understanding the relevance of an assay to the desired results in human beings, diagnosing potential problems, and providing practical approaches to overcome them. POSTERS : The top three poster presenters as chosen by the conference chairs will be invited to address the conference. Don't miss this opportunity to spotlight your work. Also, the top two GRAD STUDENT posters will win a free ride to the conference. Special thanks to our conference sponsors, CoalesiX and Symyx Renaissance SoftwareNOTE THAT E-MAIL ADDRESSES HAVE BEEN MODIFIED!!!
All @ signs were changed to ]*[ to fight spam. Before you send e-mail, you need to change ]*[ to @
For example: change joe]*[big123comp.com to email@example.com
Please let colleagues know about conference listingts at Computational Chemistry List Conference Page at http://www.ccl.net/chemistry/a/conferences/.
Please help: If you find this conference list useful but you noticed some conference missing, please consider including it here by using the Conference Submission Page. It is free but your support is welcome. You will help others!!!
|Modified: Wed Feb 1 14:42:46 2006 GMT|
|Page accessed 7014 times since Wed Feb 1 14:42:46 2006 GMT|
Please help maintain CCL: If you found that your conference is listed here, please consider supporting CCL as a Supporting Member or use other Paid Services of CCL to ensure the continuation of this useful service. We cannot do it without your help.